All posts by peferguson

Nodular Sclerosing Hodgkin Lymphoma

The most common variant of classical Hodgkin’s lymphoma (65–70% of cases), which is characterized by fibrous collagen bands that divide the lymph node into at least one nodule (fibrosis can range from scant to abundant) and neoplastic Hodgkin cells and Reed-Sternberg (HRS) cells with lacunar morphology (formalin fixation artifact with retraction of the cytoplasm).  The lymph node capsule is usually thickened.
 
Syncytial variant – prominent aggregates of neoplastic Hodgkin cells.
 
The immunophenotype of nodular sclerosing variant is shared with the other variants of classical Hodgkin lymphoma (PAX-5+, CD15+, CD30+, and CD45-).  EBV infection is not common in this subtype (10-40%).
Classical Hodgkin Lymphoma – General Information
 
Characteristic Immunohistochemical Features

References
Hematopathology. [edited by] Jaffe, ES. 1st. ed. Elsevier, Inc. © 2011.
 
Robbins and Cotran Pathologic Basis of Disease.  V Kumar, et al. 9th Edition. Elsevier Saunders. 2015.
 
WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues.  SH Swerdlow, et al. International Agency for Research on Cancer. Lyon, 2008.

Classical Hodgkin Lymphoma – Immunohistochemsitry

CHL Immunohistochemical Features:
Positive in the malignant cells in almost all cases.  Membrane staining with Golgi area positivity.
Positive in the malignant cells in a majority of cases (75-85%).  The staining pattern is similar to CD30.  It should be noted that there is a lot a variability lab to lab in the performance of the antibody.
Usually negative
Dim expression in the lymphoma cells in >90% of the cases.  Helpful in differentiating cases from anapestic large cell lymphoma, which may be CD45 negative.
Usually negative, but may have dim variable subset expression in up to 20% of cases.
Rarely positive in the lymphoma cells.
Usually positive and usually intense.
EBV
Variable
Rarely positive and usually weak if positive.
OCT-2
Negative in 90% of cases.
Negative in 90% of cases.
Negative or dim expression
Negative.
 
References
Hematopathology. [edited by] Jaffe, ES. 1st. ed. Elsevier, Inc. © 2011.
 
Robbins and Cotran Pathologic Basis of Disease.  V Kumar, et al. 9th Edition. Elsevier Saunders. 2015.
 
WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues.  SH Swerdlow, et al. International Agency for Research on Cancer. Lyon, 2008.

Classical Hodgkin Lymphoma (CHL)

NF-κB transcription factor is a common event, which may occur through EBV infection (hence some cases positive for EBV) or other mechanism.  It is thought this process results in survival of germinal center B-cells, which would otherwise undergo apoptosis.  Hodgkin lymphoma cells typically represent a small number within the lesional tissue.  Hodgkin cells secrete varying cytokines that recruit other inflammatory cells, which make up the characteristic milieu (histiocytes, plasma cells, T-cell, and eosinophils).
 
Reed-Sternberg (HRS) cells are defined by two separate nuclear lobes with large nucleoli.  Mononuclear neoplastic cells are referred to as Hodgkin cells.  There is often a spectrum in appearance of the neoplastic cells with some HRS types but they may a minority.  Granulomatous inflammation may be present in biopsy specimens, and it important not to dismiss the granulomatous inflammation as the primary pathology (especially in small biopsy samples).
Categorization
Characteristic Immunohistochemical Features:
Positive in the malignant cells in almost all cases.  Membrane staining with Golgi area positivity.
Positive in the malignant cells in a majority of cases (75-85%).  The staining pattern is similar to CD30.  It should be noted that there is a lot a variability lab to lab in the performance of the antibody.
Usually negative
Dim expression in the lymphoma cells in >90% of the cases.  Helpful in differentiating cases from anapestic large cell lymphoma, which may be CD45 negative.
Usually negative, but may have dim variable subset expression in up to 20% of cases.
Rarely positive in the lymphoma cells.
Usually positive and usually intense.
EBV
Variable
Rarely positive and usually weak if positive.
OCT-2
Negative in 90% of cases.
Negative in 90% of cases.
Negative.
 
General
Brentuximab vedotin (Adcetris) is an anti-CD30 monoclonal antibody used to treat anaplastic large cell lymphoma and relapsed or refractory Hodgkin lymphoma.  Ongoing research with promise is active in other CD30 positive neoplastic processes. 
References
Hematopathology. [edited by] Jaffe, ES. 1st. ed. Elsevier, Inc. © 2011.
 
Robbins and Cotran Pathologic Basis of Disease.  V Kumar, et al. 9th Edition. Elsevier Saunders. 2015.
 
WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues.  SH Swerdlow, et al. International Agency for Research on Cancer. Lyon, 2008.
 
Ansell SM. Brentuximab vedotin. Blood. 2014. doi:10.1182/blood-2014-06

Nodular Lymphocyte Predominate Hodgkin Lymphoma (NLPHL)

Nodular Lymphocyte Predominate Hodgkin Lymphoma (NLPHL) epresents approximately 5-10% of Hodgkin lymphoma cases (predominately male, 30-50 y/o) and has slightly different appearing neoplastic cells (popcorn cells – folded/multilobuated usually with multiple nucleoli).  The cellular background is typically composed of small lymphocytes and histiocytes.  Some plasma cells may be present at the peripheral of the nodule.  Neutrophils and eosinophils are not typically present.  The immunophenotype of lymphocyte predominate (LP) cells in NLPHL  is different from classical Hodgkin lymphoma.  The LP  cells express CD20 and BCL 6, but are typically negative for CD30 and CD15.  Dim expression of CD30 can be seen.

Continue reading Nodular Lymphocyte Predominate Hodgkin Lymphoma (NLPHL)

Blastic Plasmacytoid Dendritic Cell Neoplasm

IHC Expression Pattern
Positive
Positive
CD45RA
Positive
Positive.  Rare cases may be negative, but should express CD4, CD123, and TCL1.
Expressed in ~50% of cases (small cytoplasmic dots)
Often Positive
Negative
MPO
Negative
Negative in tissue sections (may be + by flow)
Negative
Negative
EBV-EBER
Negative
TCL-1
Positive
References
Hematopathology. [edited by] Jaffe, ES. 1st. ed. Elsevier, Inc. © 2011.

Acute Myeloid Leukemia, NOS (AML-NOS)

Immunohistochemistry in AML-NOS

AML with Minimal Differentiation (M0)
MPO
While negative by cytochemistry (by definition) a subset may have expression by flow cytometry or IHC.
CD34  
Most cases are Positive.
~50% Positive (not a specific marker of lymphoblasts)
~40% are Positive

 


AML without maturation (M1)
MPO
Usually positive
CD34
~70% of cases are positive
Often Positive
CD7
~30% of cases are positive
10-20% of cases may show expression of CD2, CD4, CD19, and CD56.

AML with maturation (M2)
CD34
Usually Positive, but may only be expressed on a subset of the blasts.
CD117
Usually Positive, but may only be expressed on a subset of the blasts.
CD7
~20-30% of cases are positive.

Expression of CD4, CD2, CD19, or CD56 is not common (~10% of cases).


Acute Myelomonocytic Leukemia (M4)
CD34
Usually Positive, but may only be expressed on a subset of the blasts (not in the monocytic derived cells).
CD117
Usually Positive, but may only be expressed on a subset of the blasts.
CD7
~30% of cases are positive.

Acute Monoblastic and Monocytic Leukemia (M5)
CD34
~30% of cases are positive (flow data)
Usually Positive, more often than CD34. (flow data)
CD7
~25-40% of cases are positive. (flow data)
~25-40% of cases are positive. (flow data)
 

Acute Erythroid Leukemia (M6)
 
ERYTHROLEUKEMIA (erythroid/myeloid)
CD71  
May show abnormal dim expression in the erythroblasts.
 
The myeloid population may excess myeloid markers similar to that of AMO with minimal maturation.
 
PURE ERYTHROID LEUKEMIA
CD34
Usually negative
CD117
+/-

Acute Megakaryoblastic Leukemia (M7)
CD41  
Often Positive
CD61
Often Positive
CD42
Less often positive (more mature platelet marker)
Usually Negative
Usually Negative
MPO
Negative
TdT
Negative
CD7
+/-
 

Acute Panmyelosis with Myelofibrosis
CD34
Usually Positive
CD117
Often Positive
MPO
Usually Negative

AML with Myelodysplasia-Related Changes

Immunohistochemistry in AML with Myelodysplasia-Related Changes

Often positive with abnormalities of chromosomes 5 and 7.  CD34 may only be expressed in a subpopulation of the blasts.
Variably positive, but may be seen more commonly in 
cases with abnormalities of chromosomes 5 and 7.
Variably positive
Variably positive
 
Other myeloid antigens may be positive.

AML with Recurrent Genetic Abnormalities

Immunohistochemistry in AML with Recurrent Cytogenetic Abnormalities

AML t(8;21)
Usually Positive
HLA_DR
Usually Positive (flow marker)
CD13
Usually Positive
Often Positive
Often Positive
CD79a  
May be Positve (Cytoplasmic)
-/+ (usually weak)
Occasional cases may be positive.  Adverse prognostic indicator.
 

AML inv(16) or t(16;16)
Usually Positive
Usually Positive
Often positive, but not specific
 
Varying expression of granulocytic and monocytic markers may be seen depending upon differentiation.

APL t(15;17) PML-RARA
Weak or negative
HLA_DR
Weak or negative (flow marker)
Often Positive (may be weak)
~20% of cases are positive, associated with a worse prognosis.
 

AML t(9;11) MLLT3-MLL
Variably Positive
Variably Positive
Often strong expression
 

AML t(6;9) DEK-NUP214
MPO
Often Positive
Usually Positive
Usually Positive
~50% are Positive
 

AML inv(3) or t(3;3) RPN1-EVI1
There is limited data available.  Some studies show CD7 may be aberrantly expressed.

AML t(1;22) RBM15-MKL1 (Megakaryoblastic AML)
CD41  
Often Positive
CD61
Often Positive
CD42
Mature platelet marker, which is less often expressed.
Usually Negative
MPO
Usually Negative
Negative
 

AML with Mutated NPM1
CD34 is usually negative.  Myeloid and/or monocytic markers may be positive.

AML with Mutated CEBPA
CD34  
Usually Positive
~50-73% of cases are positive
Usually negative
 
One or more myeloid markers are usually positive.
 
References
 

Myeloid Sarcoma

Myeloid sarcoma is essentially AML occurring outside the bone marrow.   It has been referred to by many names including leukemia cutis, granulocytic sarcoma, myeloid sarcoma, and chloroma.  Diagnosis may be difficult to make because many of the usual IHC characteristics in the bone marrow are not mirrored when AML presents in the skin or other locations.  Additionally, flow cytomtery is often not performed when lesions present in unusual locations (e.g. skin, etc.). 
 
The 2008 WHO Classification lists the following helpful IHC markers from most sensitive to least sensitive:  CD68/KP1 > MPO > CD117 > CD99 > CD68/PG-M1 > Lysozyme > CD34 > TdT > CD56 > CD61 > CD30 > CD4.
 
It is important to remember the individual markers characteristics and that some are less specific than others.  It is critical to evaluate the results using a panel of markers combined with the morphology.
Myeloid Leukemia Cutis
The following is the IHC performance from 33 cases studied at Stanford Medical Center:
IHC Marker
% Positive
97% (N=33)
MPO
42% (N=33)
94% (N=33)
CD163
25% (N=28)
47% (N=30)
Predominately Negative
Predominately Negative
References
Hematopathology. [edited by] Jaffe, ES. 1st. ed. Elsevier, Inc. © 2011.
 
Cronin DM, et al. Am J Clin Pathol2009, Jul;132(1):101-10.